EGFR and non-small cell lung carcinoma: Clinical guidelines recommend routine mutation testing and identification of EGFR mutations in all patients with NSCLC of non-squamous cell carcinoma (non-SCC) histology to identify who may benefit from approved EGFR-TKIs [6–8].